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Abstract
Although industrial researchers have been involved in interdisciplinary studies pertaining to virology for
several decades, the participation of academic chemists has been significantly increased owing to the
importance of HIV (human immunodeficiency virus), the virus which leads to the onset of AIDS (acquired
immune deficiency syndrome). The Center for Disease Control estimates that almost 20 million people have
been infected by HIV worldwide. The compelling need for effective antiviral therapies for HIVinfected
persons, together with rapid advances in understanding the molecular mechanisms of virus replication, has
resulted in an explosion of interest in antiviral agents and approaches to antiviral therapies
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Introduction
Although industrial researchers have been involved
in interdisciplinary studies pertaining to virology for
several decades, the participation of academic chem-
ists has been significantly increased owing to the
importance of HIV (human immunodeficiency virus),
the virus which leads to the onset of AIDS (acquired
immune deficiency syndrome). The Center for Dis-
ease Control estimates that almost 20 million people
have been infected by HIV worldwide. The compel-
ling need for effective antiviral therapies for HIV-
infected persons, together with rapid advances in
understanding the molecular mechanisms of virus
replication, has resulted in an explosion of interest
in antiviral agents and approaches to antiviral
therapies.
This article is organized as follows. After a review
of virus replication and current antiviral treatments,
we discuss the antiviral activity of the naturally
occurring polycyclic quinone hypericin and highlight
the necessity of light for its activity. We next focus
on how we are using molecular biology to exploit the
dependence of light for virucidal activity as a means
of specifically targeting hypericin to virus-infected
cells. We refer to this targeted light delivery as the
“molecular flashlight.” Having provided this back-
ground, the synthesis of the components of the
molecular flashlight are discussed in detail. Finally,
on the basis of what we have learned from hypercin
and its analogs, we discuss the role of light, on a
molecular level, for antiviral activity. In particular,
we point out the importance of excited-state intramo-
lecular proton transfer as a primary photophysical
process occurring in hypericin upon absorption of a
photon. This observation confirms the existence of
labile protons in hypericin. Next, on the basis of
what is known about the life cycle of the virus, we
suggest how the presence of labile protons might
contribute to virucidal activity. We also note that
hypericin possesses mechanisms of antiviral activity
that do not depend on the presence of oxygen.
Having established that hypericin has alternate
pathways of virucidal activity that do not involve
singlet oxygen, we demonstrate that it also executes
intermolecular proton transfer and that it is also
capable of protonating its surroundings.
Virus Replication and Antiviral Drugs
In general, viruses are classified by structural
elements of the virus particle (virion). All viruses
have genetic material (DNA or RNA) and some have
enzymes necessary for replication packed into a
protein shell called a capsid. Many viruses also have
a glycoprotein envelope surrounding the capsid. For
example, retroviruses (such as HIV), herpes simplex
virus (HSV), and influenza virus are all enveloped
viruses. Poliovirus, human papilloma virus, and
Ebola virus do not have viral envelopes. Viruses
replicate intracellularly and rely on host cell machin-
ery for many aspects of replication. The challenge
in designing safe, effective antiviral drugs is to
specifically interfere with virus replication with
minimal deleterious effect to the host cell. Advances
in our understanding of molecular mechanisms of
virus replication indicate that human pathogenic
viruses rely on virus-specific proteins at certain
critical points in replication. These proteins include
viral enzymes necessary for replication of viral
nucleic acid as well as proteins important in regula-
tion of virus gene expression. By identifying the
unique structural elements of a particular virus, or
unique aspects of virus replication, researchers may
begin to rationally design specific inhibitors.
Replication of animal viruses can be viewed as a
series of steps, beginning with attachment of the
virus to the host cell and concluding with release of
infectious virions (an example is shown in Figure 1).
The first step in the virus life cycle is entry of the
* To whom correspondence should be addressed.
† Department of Microbiology, Immunology, and Preventive Medi-
cine.
523Chem. Rev. 1996, 96, 523−535
0009-2665/96/0796-0523$25.00/0 © 1996 American Chemical Society
virion into a host cell. Initially, the virus interacts
with a receptor on the surface of the host cell and
penetrates the host cell membrane. In some cases,
the cell membrane may engulf the virion (a process
called endocytosis), or viral entry may proceed by
direct fusion with the host cell membrane. Once
inside the cell, the virus uncoats and the viral nucleic
acid is released into the cell. In many cases, regula-
tory proteins are transcribed and translated prior to
synthesis of viral nucleic acid and viral structural
proteins. Eventually, assembly of the intact virion
takes place and the newly generated virions are
released from the host cell by two processes. In a
process called budding, the virion passes through the
host cell membrane without disruption of the cell. In
the other process, the cell bursts, releasing virus
particles all at once. Once the new virions are
released, they then infect other host cells.
Any of the steps of the virus life cycle could, in
principle, be disrupted, leading to the destruction of
the virus. Disruption of nucleic acid synthesis is
perhaps the most common mode of viral inactivation.
For example, nucleoside analogs such as AZT and
DDI lack the 3′-hydroxyl group, and function as chain
terminators. That is, once AZT or DDI are incorpo-
rated into the DNA, they prevent the completion of
the DNA molecule.104 Both compounds exhibit anti-
HIV activity in vivo; however, the eventual emer-
gence of drug-resistant viral variants likely contrib-
utes to the fact that these treatments may delay, but
do not completely block, the progression to clinical
disease in HIV-infected persons.
Other stages in the virus replication cycle are also
amenable to antiviral therepies. Amantidine, an
antiviral agent which is clinically useful against the
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influenza A virus, blocks the uncoating of the influ-
enza A virus by acting as an ion channel blocker. This
prevents the establishment of a pH gradient across
the viral membrane which normally acts to trigger
the disruption of the capsid protein.1 Inhibition of
late stages of HIV replication is being pursued though
development of protease inhibitors. HIV-1 protease
is a virus-encoded aspartic proteinase which is re-
quired for maturation of infectious HIV-1.98 A num-
ber of small peptide molecules which resemble the
enzyme substrate have been developed which com-
pete with HIV-1 protease and are in clinical use.2-4
A relatively new approach to antiviral therapy is
the application of somatic gene therapy. Several
strategies have been proposed to target antiviral
genes to cells that support replication of HIV-1.5 The
exogenous gene product may interact directly with
HIV-1 to inhibit specific stages of virus replication,
or may result in destruction of virus-infected cells.
In both cases, the overall goal is to prevent further
spread of infectious virus.
Strategies which interfere with HIV-1 replication
include expression of decoy RNAs,6-9 antisense
sequences,10-13 ribozyme RNAs,9,14-17 and production
of transdominant mutant proteins.18-25 In many
cases, these therapies target the viral regulatory
proteins Tat and Rev. These proteins regulate HIV-1
gene expression at the transcriptional (Tat) or post-
transciptional (Rev) level and are required for pro-
duction of infectious virus. Both Tat and Rev are
RNA-binding proteins, and current gene therapy
approaches are directed toward preventing, or inhib-
iting, the specific RNA-protein interaction. A second
gene therapy approach involves elimination of virus-
infected cells. Direct killing of HIV-1-infected cells
has been achieved through expression of cytocidal
genes, such as diptheria toxin,26 or through expres-
sion of genes which render the cells susceptible to
drug treatment. For example, cells expressing the
herpes simplex virus thymidine kinase gene are
susceptible to ganciclovir, whereas normal cells are
not.27,28 The use of these therapy strategies requires
that gene delivery methods selectively target virus-
infected cells and/or are specifically expressed in
virus-infected cells. Restricting expression of a sus-
ceptibilty gene to HIV-1-infected cells can be achieved
by including HIV-1 sequences which interact with
viral regulatory proteins Tat and Rev such that the
delivered gene is expressed in HIV-1-infected cells,
but not in normal cells. For example, Tat increases
HIV-1 transcription by binding to a highly structured
RNA sequence, termed TAR, present at the 5′-end of
all viral mRNAs. The inclusion of TAR sequences
in the promoter controlling the susceptibility gene
results in increased levels of the toxic protein in HIV-
1-infected cells as compared to noninfected cells.
When combined with gene delivery systems that
target genes to HIV-1 susceptible cells,29,30 such
strategies would theoretically reduce background
toxicity.
The high rate of virus replication and mutation
often results in the development of drug-resistant
mutations and limits the long-term usefulness of
many antiviral drugs. Antiviral drugs which have
more general toxic effects are less susceptible to virus
mutation and may be amenable to gene therapy
approaches that target virus-infected cells rather
than virus-specific proteins. We have therefore
focused our attention on the development of a therapy
that would theoretically reduce the appearance of
drug-resistant mutants. Our group has character-
ized the antiviral activity of hypericin using equine
infectious anemia virus (EIAV) as a retroviral model
of HIV.31-38 EIAV is a well-suited model for for
studies of antiviral agents effective against HIV since
Figure 1. Strategies for blocking HIV replication. This
scheme depicts the simple life cycle of HIV replication.
Strategies that interrupt retrovirus replication in general,
and those for HIV in particular (boxed), are outlined. AZT,
ddC, ddA, and ddI are deoxynucleotide analogs that cause
chain termination, PPF is phosphonoformate, a reverse
transcriptase inhibitor, and RIF is R-interferon. The figure
is taken from Field’s Virology, 2nd ed.; Fields, B. N., Knipe,
D. M., Eds.; Raven Press, Ltd.: New York, 1990; Chapter
53, p 1539, and is used with permission.
Development of a Molecular Flashlight Chemical Reviews, 1996, Vol. 96, No. 1 525
it is an enveloped lentivirus that is structurally,
genetically, and antigenically related to HIV.39-41 Our
studies have demonstrated that hypericin, in the
presence of ambient room light, reduces the infectiv-
ity of cell-free stocks of EIAV by 99.99%.31 Subse-
quently, we reported that light was required for the
virucidal activity of hypericin,32 a finding later con-
firmed by others using HIV-1.42,43 More recently, we
have devised a strategy to place in the proximity of
hypericin a chemiluminescent light source so that
photodynamic therapy can be extended to all regions
of the body.33 Examination of the structural and
chemical basis for light-activated virucidal activity
has resulted in new concepts of how these compounds
may inactivate the virus.34-36 These studies repre-
sent the fruit of a successful interaction of synthetic
chemistry with molecular virology and physical chem-
istry and illustrate how such interactions may lead
to novel antiviral therapies.
Antiviral Activity of Hypericin
Hypericin (1) and its hydroxylated analog, pseudo-
hypericin (2), are naturally occurring quinones which
exhibit potent in vitro inhibitory activity against
several enveloped viruses, including retroviruses,
herpes viruses, and human immunodeficiency virus
(HIV).31,32,42-47 Hypericin is the pigment in the plant
St. John’s wort and has a long history of use as a
folk medicine for treating ailments as wide ranging
as bed wetting, headache, rheumatism, and depres-
sion.48 Extracts from St. John’s wort can be pur-
chased in health food stores and have been taken
orally by individuals infected with HIV.49,50 Hyperi-
cin is also currently being used in clinical trials for
HIV.49-54 Light-skinned subjects, both human and
animals, can develop erythema (irritation and red-
ness of the skin), whereas dark-skinned individuals
are much less susceptible to these effects. Studies
of photosensitization in animals have shown that the
extent of phototoxicity varies with the dosage of the
photosensitizer and with the subsequent exposure to
light.96 In AIDS clinical trials, early reports found
classical symptoms of photosensitization with rela-
tively high doses of hypericin (0.5 mg/kg).105 How-
ever, as recently as 1993 Steinbeck-Klose andWernet
reported the long term (40 month) successful treat-
ment of HIV-infected persons with no reported side
effects.52 In studies of hypericin as an antidepres-
sant, therapeutic doses (250 íg three times per day)
were achieved with no significant toxic side effects.106
In vivo application of hypericin for treatment of
HIV-1 infections would be significantly increased if
therapeutic doses were below levels associated with
phototoxicity. This may be possible if the mechanism
of antiviral activity of hypericin were better under-
stood, thereby allowing the design of compounds with
increased virucidal activity and, subsequently, low-
ered therapeutic dose. Alternately, it may be possible
to design novel, light-independent compounds which
exert a similar mechanism of antiviral activity. Over
the last several years, our group has studied the
photophysical properties of hypericin and related
compounds in order to better understand the viru-
cidal properties of hypericin.
In 1991, we reported that light was required for
the antiviral activity of hypericin.32 Interestingly, the
fluorescent light from the laboratory lighting was
sufficient to allow observation of in vitro activity.
More recent studies demonstrated the tumoricidal
activity of hypericin and found it to be dependent on
the presence of light and oxygen.56 Therefore, hy-
pericin is similar to other photosensitizers that, when
activated by light, exert potential therapeutic effects
against tumors and some viruses. Related com-
pounds such as stentorin, hypocrellin A, and many
porphyrins and phthalocyanines are members of this
class.57 There is a rapidly-expanding literature on
the use of photodynamic compounds to inactivate
tumor cells and virus-infected cells (photodynamic
therapy) that has been collated in excellent reviews
by Song and Diwu.58,99
In recent years the therapeutic use of photosensi-
tizers has emerged as a promising tool in cancer
chemotherapy.59 The mechanism of cytotoxicity most
probably involves the generation of singlet oxygen by
the light-excited photosensitizer.60,61 Hypericin pro-
duces singlet oxygen very efficiently (with a quantum
yield of 0.7362), and singlet oxygen is most probably
involved in hypericin-mediated killing of tumor cells
in vitro.56 Other studies have suggested that the
antiviral activity of hypericin is due to the production
of singlet oxygen.42,43,47,63 However, the excited-state
reactivity of hypericin extends well beyond the pho-
tosensitization of oxygen to form singlet oxygen. In
fact, recent studies suggest that antiviral activity
may be due to complex mechanisms involving the
superoxide anion and hypericinium ion. Redepen-
ning and Tao64 have measured the formal potential
of hypericin in DMSO by cyclic voltametry and
concluded that, in its excited state, hypericin is both
a good oxidizing and reducing agent. Diwu and Lown
observed both singlet oxygen and superoxide radical
upon illumination of hypericin with 580-nm light
under aerobic conditions.65 They also indirectly
observed the formation of a semiquinone radical
species in the absence of oxygen. Mazur and co-
workers have obtained similar results.66,67
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We have demonstrated that hypericin undergoes
an excited-state intramolecular proton transfer and
that it is an excited-state proton source. We have
hypothesized that photogenerated protons may be
important in the antiviral activity of hypericin.35-38
Our finding that hypericin retains antiviral activity
under hypoxic conditions34 underscores the potential
importance of these excited state intermediates in the
virucidal activity of hypericin.
The mechanisms by which photoactivated hyperi-
cin targets and inactivates viruses are not clear.
Because of the potential importance of hypericin as
a therapeutic agent for treatment of HIV-1 infection,
most information available on the antiviral activity
of hypericin derives from studies of HIV42,43,47,68 and
related retroviruses.31,32,47 These studies have dem-
onstrated that hypericin is able to inactivate cell-free
virus and to inhibit virus production from infected
cells. Meruelo and co-workers43,69 have observed
that, in the presence of light, hypericin induces
significant changes in the HIV-1 capsid protein, p24,
and the p24-containing gag precursor, p55, as indi-
cated by Western blot analysis. They have also
observed that recombinant p24 in the presence of
light forms an immunoreactive material of a molec-
ular weight of 48 kDa. They have consequently
suggested that cross-linking and other alterations of
p24 occur and that such alterations may inhibit the
reverse transcriptase activity. In other studies,
inhibition of gp120 binding was observed under
conditions of more intense illumination.43 Together,
these results indicate that observed differences in the
biological effects of photoactivated hypericin may
depend on the level of irradiance and concentration
of photosensitizer.
Molecular Flashlight
In vivo applications of hypericin for treatment of
HIV-1-infected individuals is hampered by the de-
pendence on light for optimal antiviral activity.
Some therapeutic benefit may be achieved due to the
fact that the longer wavelengths of light at which
hypericin absorbs (Figures 2 and 6) are fairly good
at penetrating the body. Therefore, systemic irradia-
tion following hypericin treatment may result in a
reduction in viremia and destruction of virus-infected
peripheral blood leukocytes. Hypericin has been
tested in phase I clinical trials, and there is some
evidence that long term treatment may slow the
progression of clinical disease. However, this thera-
peutic approach may be of limited effectiveness in
elimination of HIV-1 in lymph nodes. Virus replica-
tion and persistence in lymphoid tissue play a major
role in HIV pathogenesis.70-72 Our approach has
been to develop a strategy to place in the proximity
of hypericin a chemiluminescent light source so that
photodynamic therapy can be extended to all regions
of the body. Moreover, it occurred to us that the
requirement for light activation might enable us to
develop a drug which would target only virus-infected
cells.
An expedient choice for the light source is luciferin
(Figure 2). The reaction of luciferin with the enzyme
luciferase and molecular oxygen produces light in the
520-680-nm region with a quantum efficiency of
about unity.73 Hypericin absorbs light strongly in
this range, suggesting that some combination of
energy transfer and reabsorbtion between the prod-
uct of the chemiluminescent reaction (Figure 2) and
hypericin may be sufficient to effect significant
antiviral activity. In vitro studies indicated that, at
high concentrations of hypericin, there is approxi-
mately a 10-fold reduction of viral infectivity under
conditions where the sole source of excitation was the
chemiluminescent luciferin/luciferase system (Figure
3). The chemiluminescent light-generating system
was not, however, as effective in activating hypericin
as illumination from a continuous source. Further
experiments were done to determine if increased
antiviral activity could be achieved by an increase
Figure 2. Above are displayed crucial intermediates in
the production of firefly chemiluminescence.33 Luciferin (a)
is catalyzed by the enzyme luciferase in the presence of
ATP, Mg2+, and O2 to form the high-energy four-member
peroxide or dioxetanone intermediate (b). This intermediate
subsequently decarboxylates to form the chemilumnescent
species oxyluciferin (c). Below is presented the spectral
overlap between the visible portion of the absorption
spectrum of hypericin and the chemiluminescence from the
luciferease-catalyzed oxidation of luciferin. The reaction is
carried out at 25 °C in glycylglycine buffer containing 2.67
 10-7 M luciferase; 1.18  10-6 M luciferin, and 5  10-5
M ATP. The efficiency of the nonradiative energy transfer
in a Fo¨rster energy transfer mechanism is given by Ro, the
critical distance, which in this case is 100 Å. Both radiative
as well as nonradiative energy transfer are likely to occur
in this system. If we identified a way to ensure that the
interaction of luciferin with luciferase in the presence of
hypericin took place only in virus-infected cells, then we
would have a selective and effective antiviral therapy.
Development of a Molecular Flashlight Chemical Reviews, 1996, Vol. 96, No. 1 527
in the amount of light initially available for hypericin
activation. A linear decrease in viral infectivity was
observed when the concentration of luciferase was
varied in the presence of a constant concentration of
hypericin (Figure 4).
One reason that the chemiluminescent system is
not as effective in activating the antiviral activity of
hypericin as is a continuous source of illumination
is that there is most likely a suboptimal distance and
orientation between the donor and acceptor. Never-
theless, energy transfer between luciferin/luciferase
and hypericin is possible even when the donor and
the acceptor are not constrained to be at a fixed
distance or orientation with respect to each other or
when there is no covalent attachment between these
two reactants. Most importantly, the amount of light
transferred to hypericin under these conditions is
sufficient to produce significant antiviral activity.
The finding that the antiviral activity of hypericin
can be activated by chemiluminescent reactions may
have important implications for the development of
novel methods for treatment of viral infections such
as HIV-1. In vivo generation of luciferase could be
accomplished using gene therapy approaches that
employ luciferase as a susceptibility gene. Moreover,
expression of the luciferase gene could be regulated
if placed under the control of a promoter containing
HIV TAR sequences, limiting photoactivation of
hypericin to virus-infected cells. This would result
in a “molecular flashlight” in which light is turned
on or off, depending on the presence of the HIV-1
transacting viral protein Tat.
Synthesis of Hypericin, Its Analogs, and
Components of the Molecular Flashlight
With a technique for activating hypericin now
available, we focused our efforts on the problem of
drug targeting. Any in vivo application of chemilu-
minescent activation of hypericin would, of course,
require a delivery system that ensures a high local
concentration of hypericin and luciferin/luciferase. In
order to avoid the problems inherent in requiring
three separate compounds to come together in the
virus-infected cell, we decided to covalently connect
hypericin and luciferin. This tack required an ef-
ficient synthesis of both hypericin and luciferin.
Although both compounds are commercially avail-
able, hypericin is available in limited quantities and
is quite expensive ($400/10 mg). Luciferin is also
rather expensive ($86/10 mg). Apparently, much of
the luciferin supply comes directly from fireflies.
Existing syntheses of hypericin begin with emodin
(3). Steglich and Rodewald independently reported
the synthesis of hypericin in one step, albeit in
approximately 1% yield, by the treatment of emodin
with dilute aqueous base at 100 °C for ten days.75
Apparently, the coupling of two emodin molecules
affords dimer 4 as the predominant initial product.
The initial dimer that could lead to hypericin is a
minor product. Banks, Cameron, and Raverty also
reported a synthesis of hypericin from emodin.76
Their synthesis is depicted below. This synthesis
involves the reduction of emodin to an anthrone,
coupling the anthrone with ferric chloride to a
Figure 3. Effect of chemiluminescence on the antivral
activity of hypericin. EIAV was incubated in the dark at
room temperature in the presence of 0.8 íM luciferase, 10
íM luciferin, 2 mM ATP, and increasing amounts of
hypericin (O). Control samples include those containing
virus and hypericin only (b) and parallel samples exposed
to ambient room light (9). Infectious virus was titrated by
using a focal immunoassay,31,33,34,103 and the results are
reported as focus forming units (FFU) per milliliter of
reaction mixture.
Figure 4. Effect of luciferase concentration on antiviral
activity of hypericin after chemiluminescence. EIAV was
incubated with 0 (b) or 10 (O) íg of hypericin/mL in the
presence of 5 mM luciferin, 2 mM ATP, and increasing
amounts of luciferase. Reaction mixtures were incubated
in the dark for 30 min at room temperature, and results
are reported as FFU/mL of reaction mixture.
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bianthrone and oxidation of the bianthrone in am-
monia with oxygen.
Although the yield on a millimole scale is reported
to be good, this reaction appears to be difficult to scale
up to generate gram quantities of hypericin. Another
synthesis of hypericin from emodin has been reported
in a patent.100 This reaction is depicted below.
In designing hypericin conjugates for antiviral
therapy, it is important to know which functional
groups on hypericin are essential for potent antiviral
activity. To address this question, we synthesized
analogs 5-10.
We had previously reported that hydroxylated
anthraquinones, hydroxylated perylenequinones, and
polycyclic quinones which resembled hypericin did
not exhibit significant antiviral activity.31 Analogs
537,77 to 10 assess the relative importance of hydroxyl
groups on the phenanthro-perylene ring. Analog 5
is a known compound that was synthesized from
anthrone in two steps.77 Analog 6was prepared from
the anthrone of 1,3,6,8-tetramethoxyanthraquinone.
On the basis of ultrafast spectroscopic studies of
hypericin and related hydroxyquinones, we have
proposed that the hydroxyl groups peri to the quinone
carbonyl groups contribute to the antiviral activity
in the presence of oxygen and are essential to the
antiviral activity in the absence of oxygen.34-38 The
ultrafast spectroscopic measurements of analog 6will
test this hypothesis.
Analog 7 was synthesized as shown below. Analog
10 was produced in low yield as a byproduct of the
synthesis of 7.
Analog 8 was readily prepared from 1,3,6,8-tet-
rahydroxyanthraquinone by coupling of the corre-
sponding anthrone followed by oxidative cyclization.
We have found that lead tetraacetate is a superior
oxidant in this case.
Anthrone analog 9 was efficicently prepared from
1,3,6,8-tetrahydroxy-2,7-dimethylanthraquinone (11),
which in turn was synthesized from 2,6-dichloroben-
zoquinone by a double Diels-Alder reaction. Since
anthraquinone 11 has only one site for radical
coupling, we tried to make 9 using the conditions
developed by Steglich. Unfortunately, after 11 was
treated with base for 7 days at 100 °C, only starting
material was recovered. However, subjecting 11 to
reduction (SnCl2), coupling (FeCl3), and oxidation
(PbOAc4) furnished analog 9 in 68% yield.
Analogs 5-10 were tested for anti-retroviral activ-
ity in vitro using EIAV.32 Antiviral activity is
determined by the amount of EIAV present, as
measured by the number of focus-forming units per
milliliter (FFU/mL)32 (Table 1). Analogs 5,31 8,107 and
9 did not exhibit any antiviral activity, and analogs
6 and 10 possess antiviral activity that is consider-
ably reduced with respect to hypericin.
On the basis of the discussion of excited-state
processes below, it is tempting to attribute the
absence of antiviral activity in 5 and 6 to the absence
of labile protons. It is possible, however, that 5 and
6 produce much less singlet oxygen than does hyper-
icin, and we have not ruled this out. The UV-vis
spectrum of 9 resembles that of deprotonated hyperi-
cin. Again, it is tempting to attribute its reduced
antiviral activity to the absence of labile protons.
Structurally, the differences between 8 and 10 are
very slight (a hydrogen atom substituted by a methyl
group). An explanation for the reduced antiviral
activity in 10 and the absence of antiviral activity of
8 is that because 10 and 8 contain, respectively, four
and three more hydroxyl groups than does hypericin,
these molecules are more soluble in water than
hypericin. Consequently, 10 and 8 are not as ef-
ficiently driven into the viral membrane. It is well-
known that hypericin is exceedingly insoluble in
water except at very acidic or basic pH (see below).
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The antiviral activity of hypericin and its analogs
is likely the net result of an interplay between the
redox potential and the molecule’s ability to partition
between the cell membrane and water. The con-
struction of conjugates that retain the potent anti-
viral activity of hypericin seems limited to function-
alization of the hydroxyl groups not involved in
hydrogen bonding to the carbonyl group.
The analog study also provided valuable insight
into the synthetic limitations involved in the prepa-
ration of a suitable tethered molecule. In particular,
the high antiviral activity of 7 (comparable to that
of hypericin) appears to dictate the choice of sites for
connection of luciferin to hypericin. In light of the
above information, we prepared the tethered mol-
ecule 12. Since esters of luciferin do not react with
luciferase, this tethered molecule must be cleaved in
order to afford luciferin. Cellular enzymes that
cleave esters are readily available in host cells.
Therefore, we reasoned that, once compound 12
passed through the cell membrane, it would soon be
cleaved into the two components. Concerns relating
to subcellular localization of the luciferase and hy-
pericin and luciferin could readily be evaluated. An
important result is that the synthesis of 12 allows
us to test experimentally the ability of the molecular
flashlight to inhibit virus replication in infected cells.
Using Molecular Biology To Target the Antiviral
Activity of Hypericin
As a model system for development of inducible
chemiluminescence, we constructed a plasmid con-
taining the promoter region of EIAV inserted up-
stream of the gene for luciferase (pMA-1LTRLuc).
This luciferase plasmid was cotransfected with a
neomycin resistance plasmid (pSV2Neo) into Cf2th
cells (ATCC CRL1430) using calcium phosphate
coprecipitation. Cells were selected for neomycin
resistance, and the level of luciferase activity was
quantitated as a function of light generated following
the addition of 400 íM luciferin to 10-fold serial
dilutions of cell lysate.
Positive cells were subcultured, and parallel cul-
tures were infected with the MA-1 isolate of EIAV.
Chemiluminescence assays were done to determine
if increased levels of luciferase expression occurred
in virus-infected cells. Results (Table 2) indicated
that luciferase expression increased 10-1000 fold in
virus-infected cells, as compared to noninfected cells.
The matched cell lines 18-4 and 18-4/MA-1 provided
a useful model to test the tethered compound 12.
Specifically, we wanted to know if chemiluminescent
activation of hypericin would reduce production of a
lentivirus in cells expressing luciferase.
Cells infected with EIAV (Cf2th/EIAV) and EIAV-
infected cells expressing the luciferase gene (18-4/
EIAV) were treated with the tethered compound 12
and incubated at 37 °C for 1 h. After extensive
washing, culture supernatant was sampled from each
well and virus production was quantitated. Results
indicated that production of infectious virus was
reduced at least 10-fold in 18-4/EIAV cells treated
with 12 as compared to untreated cells; no reduction
in infectious virus was observed in Cf2th/EIAV.
These results suggest that treatment of lentivirus-
infected cells expressing the luciferase gene with a
hypericin-luciferin tether can generate sufficient
chemiluminescence to activate the antiviral activity
of hypericin. Current efforts are focused on optimiz-
ing this system for sustained, high levels of antiviral
activity in persistently infected cells.
Excited-State Processes in Hypericin and Their
Role in Light-Induced Antiviral Activity
Elucidating the reactivity of excited-state hyper-
icin and the subsequent reactivity of molecules
that it encounters is essential for understanding
the light-induced mechanism of antiviral activ-
ity32,42,43,47,62,64-67,69,78 as well as for developing optimal
antiviral agents or alternative antiviral strategies.
Table 1. Antiviral Activity of Hypericin Analogs Table 2. Fold-Transactivation of Luciferase
Expression by EIAV in Stable Cell Lines Transfected
with pMA-1LTRLuc
nM luciferase
cell clone uninfected MA-1 infected fold-increase
13-2 0.13 1.9 15
13-4 0.008 0.95 118
14-1 0.14 1.0 7
14-2 0.19 1.5 7
14-3 0.02 1.1 55
17-1 0.007 0.65 9
17-4 0.017 1.7 100
18-1 0.015 0.66 44
18-2 0.023 2.1 91
18-3 0.006 0.74 123
18-4 0.002 2.0 1000
19-1 0.016 1.5 94
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The mechanism of photosensitization by a given
molecule in its excited state can be classified into two
types of processes56,79 (Figure 5). In type I processes,
the excited-state photosensitizer interacts first with
the substrate, which may go on to react with another
reagent, which is usually oxygen. In type II pro-
cesses, the excited-state photosensitizer interacts first
with oxygen, thus producing singlet oxygen, which
subsequently goes on to react with the substrate.
We36-38 have questioned the relative importance of
singlet oxygen in the toxicity of hypericin toward HIV
and related viruses. For example, hypericin is closely
related,80 both structurally and spectrally, to the
photoreceptor of the protozoan ciliates Stentor coeru-
lus80,81 and Blepharisma japonicum.82 This photore-
ceptor confers upon the organism its biologically
necessary photophobic and phototactic responses.
Under conditions of ambient light the stentorin
chromophore and hypericin are nontoxic to the
organism. On the other hand, the singlet oxygen
produced from these chromophores is toxic to S.
coerulus under high light flux (5000 W/m2).83 It is
an open question, therefore, whether the limited
exposure to room light in our experiments32 and those
of other workers42,43,47,69 is toxic to EIAV, HIV, and
other enveloped viruses because of photosensitized
generation of singlet oxygen by hypericin or because
of the presence of additional nonradiative decay
processes of the excited states of hypericin.
Steady-State and Time-Resolved Spectroscopy of
Hypericin and Its Analogs: Excited-State Proton
Transfer
We have provided the first detailed investigation
that uses both 1-ps time resolution and a white-
light continuum to examine and to unravel the
excited-state primary photoprocesses of hypericin and
have suggested that the excited-state transients we
observe, coupled with data from model compounds,
can be interpreted in terms of tautomerization36-38
based on the following observations.
(1) Model compounds demonstrate that a proto-
nated carbonyl group is required in order to obtain
hypericin-like absorption and emission spectra.
Figure 6 gives the steady-state absorption and
fluorescence spectra of hypericin in DMSO. In
contrast to hypericin, its deshydroxy analog, meso-
naphthobianthrone (5), is nonfluorescent in the apro-
tic solvents DMSO (Figure 7a) and CH3CN. When,
however, 5 is dissolved in a protic solvent such as
methanol (in which it is only sparingly soluble), a
fluorescence band appears with a maximum at 467
nm (Figure 7b). Finally, dissolving 5 in a strong acid
Figure 5. Type I and type II photosensitization processes.
Type I and II processes are respectively distinguished by
whether the photosensitizer encounters the substrate or
O2 first.
Figure 6. Normalized fluorescence spectrum (dashed line)
and absorption spectrum (solid line) of hypericin in DMSO.
The spectra of hypericin are very similar in all solvents in
which it is soluble with the exception of shifts in absorbance
and emission maxima. (Hypericin in water at pH values
between 3 and 11 is barely, if at all, soluble and is
nonfluorescent.) The steady-state emission spectrum bears
a “mirror symmetry” relationship to the visible portion of
the abosrption spectrum. We attribute this part of the
absorption spectrum to the presence of ground-state tau-
tomer.
Figure 7. Normalized fluorescence spectra (dashed line)
and absorption spectra (solid line) of the hypericin analog
lacking hydroxyl groups, mesonaphthobianthrone. The
solvents used are DMSO (a), methanol (b), and sulfuric acid
(c).
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such as sulfuric or triflic acid generates a fluorescence
spectrum that has nearly the same shape as that of
hypericin in DMSO and that is blue-shifted from the
hypericin spectrum by about 14 nm. The emission
maximum of 5 is 584 nm. These results demonstrate
the importance of a protonated carbonyl group for
producing a fluorescent hypericin-like molecule.
(2) Time-resolved absorption (stimulated emission)
spectra and kinetics indicate that the hypericin
emission spectrum grows in on a 6-12-ps time scale.
On the basis of the model compounds, the rise time
for the appearance of the hypericin emission is taken
as evidence for an excited-state proton transfer.
Figure 8 is very instructive in this regard. In sulfuric
acid, where all the carbonyl groups are expected to
be protonated, the excited-state transient appears
instantaneously. On the other hand, in a solvent
such as DMSO, the transient appears with a finite
rise time. The excited-state absorbance transients
are of particular interest due to the earlier observa-
tions and suggestions of Song and co-workers84,85 that
the excited states of hypericin-like chromophores
produce protons upon photoexcitation.
Potential Antiviral Role of Excited-State
Processes: O2 Is Not Required for Photoinduced
Antiviral Activity of Hypericin
The influenza A virus provides an interesting
example that demonstrates the importance of pH in
viral infectivity. The influenza A virus consists of
an envelope comprised of a lipid bilayer membrane
and associated membrane proteins. This envelope
surrounds the genomic RNA, which is protected by
capsid proteins. The envelope of influenza virus A
contains two proteins the function of which in the
virus life cycle is pH dependent:93 hemagglutinin
(HA) and M2. The influenza virus binds to the cell
surface by means of HA, and it enters the cell
through receptor-mediated endocytosis. Within the
endosome, the low pH (5-6) causes a conformation-
al change in HA, which results in the fusion of the
viral membrane with the membrane of endosomal
vesicles inside the cell. M2 spans the viral membrane
and functions as an ion channel to modulate the pH
within the virion and facilitate the uncoating of the
genomic RNA. Thus, changes in ion concentration
are required for influenza virus entry and uncoating.
To explore the possible role of excited-state proton
transfer in anti-retroviral activity, we have compared
the antiviral activity of hypericin under aerobic and
hypoxic conditions.34 Hypericin is toxic in the pres-
ence and the absence of oxygen (although the data
suggest that hypericin in a hypoxic environment does
not inactivate EIAV as effectively as in an oxygenated
environment.) These results demonstrate that direct
interaction of hypericin itself with the virus (type I
mechanism) can be important for the remarkable
antiviral properties of hypericin. The relative impor-
tance of type I and type II mechanisms of hypericin
under normal biological conditions is as yet unclear.
It is useful to consider our experiments in the
context of other reports on the biological activity of
hypericin. For example, the stentorin chromophore
is toxic to S. coerulus83 under high, but not ambient
or low, light flux. Also, Meruelo and co-workers42,43
found that, under ambient lighting conditions, hy-
pericin did not inhibit the binding of gp120 to CD4
cells and that it did not inhibit the formation of
syncytia (large, abnormal multinucleated cells formed
by the fusion of infected cells with uninfected CD4
cells).42,43 On the other hand, inhibition of gp120
binding was observed under conditions of more
intense illumination: i.e., when samples were placed
10 cm away from a fluorescent light source for 30
min.43
Therefore, the relative importance of type I and II
mechanisms in virus inactivation may depend on the
intensity of light. Under high irradiance, the forma-
tion of singlet oxygen by a type II mechanism would
be predominant, whereas under low irradiance the
antiviral activity would be primarily due to a type I
reaction. Such reasoning may explain the differences
among investigators in characterizing the antiviral
mechanism of hypericin cited above. At high irradi-
ance, there is both inhibition of gp120 binding and
inhibition of cell fusion,42,43 events that depend on
interactions between virus and cell membranes.
Interestingly, the effects are not reported to occur at
low irradiance,42 where inhibition is associated with
alterations in the viral capsid protein. This may
indicate that type II reactions target the viral mem-
brane, whereas type I reactions may attack other
stages in the life cycle of the virus. This may also
explain the absolute dependence on oxygen for the
anti-tumor effect of hypericin.56
We are performing similar investigations on the
perylene quinone analog of hypericin, hypocrellin.
Hypocrellin has been observed to have light-induced
antiviral activity against HIV.87 Our measurements
Figure 8. Comparison of the rise time for the formation
of excited-state transients. This rise time is finite for
hypericin in an aprotic solvent where a portion of the
ground-state population is not tautomerized (DMSO). But
in a solvent where the entire ground-state population is
protonated (H2SO4), the rise time is instantaneous. The fits
to the data are as follows. DMSO: ìprobe ) 610 nm, ¢A(t)
) 0.23 exp(-t/9.6) - 0.41. H2SO4,ìprobe ) 630 nm, the
transient appears within the time resolution afforded by
the system, and the excited state formed is long-lived on
the time scale of the measurement.
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indicate the following:102 (a) Hypocrellin exhibits
excited-state transients that are longer than those
observed in hypericin but that can also be assigned
to intramolecular proton transfer. For example, the
rise time for the induced absorption is instantaneous
in H2SO4, where the carbonyl protons are all expected
to be protonated. (b) We have found, however, that
unlike hypericin, hypocrellin requires oxygen for
antiviral activity. (c) Unlike hypericin, hypocrellin
does not display light-induced acidification of the
solvent medium in measurements analogous to those
performed upon hypericin (see below).
The absence of light-induced acidification in hypo-
crellin and its absolute dependence upon oxygen for
antiviral activity are consistent with and support our
previous interpretation of the data for hypericin:
namely, that hypericin is an excited-state proton
source and that protons may play a crucial role in
antiviral activity. (Despite this interpretation, we
have not dismissed and are currently investigating
the possibility that hypericin also executes relevant
excited-state redox chemistry.)
Light-Induced Acidification by Hypericin
Recent results from our laboratory indicate that
hypericin does indeed act as an excited-state proton
source.35 Steady-state illumination of a solution
containing hypericin effects a pH drop as monitored
by the indicator, BCECF (2′,7′-bis(2-carboxyethyl)-
5-(and 6-)carboxyfluoroscein). When hypericin and
an indicator dye, 3-hexadecanoyl-7-hydroxycoumarin,
are both imbedded in vesicles, hypericin is observed
to transfer a proton to the indicator within a time
commensurate with its triplet lifetime. Proton trans-
Figure 9. (a) Transient absorption at 400 nm of 3-hexadecanoyl-7-hydroxycoumarin subsequent to excitation of hypericin
with a 500 ns pulse at ìex ) 490 nm. Both the indicator (23.3 mM) and hypericin (21.0 mM) are contained in the bilayer
of DPPC vesicles at pH 8.4. The decrease in the anionic form of the indicator owing to excited-state protonation by hypericin
monitored by a transient reduction of the induced bleach of the anionic form of the indicator at 400 nm. ¢A(t) ) -0.012
exp(-t/32 ms) - 0.0050 exp(-t/170 ms). The control experiment for hypericin alone in vesicles at pH 8.3 yields a trace
that is fit to the form ¢A(t) ) -0.0062 exp(-t/15 ms) - 0.0067 exp(-t/55 ms) + 0.0080. A second control experiment using
only the indicator alone in vesicles at pH 8.3 yields the trace about zero. This trace demonstrates that in the absence of
hypericin no transient absorption is induced in the indicator at 400 nm subsequent to excitation at 490 nm. (b) Induced
bleaching and its recovery at 400 nm for 3-hexadecanoyl-7-hydroxycoumarin and hypericin in DPPC vesicles at acidic and
basic pH; ìex ) 490 nm. (c) Induced bleaching and its recovery at 400 nm for 3-hexadecanoyl-7-hydroxycoumarin and
hypericin in DPPC vesicles in oxygenated and deoxygenated solution: ìex ) 490 nm. The absence of a signal in the
oxygenated sample is taken as proof that the triplet state of hypericin is responsible for the protonation event. (Under
oxygen levels at which the signal is quenched, hypericin is still fluorescent and the indicator absorption spectrum remains
unchanged. Consequently the absence of the signal cannot be a result of quenching the singlet state or of destruction of
the indicator.)
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fer to the indicator is not observed when the indicator
is protonated or when the system is oxygenated.
Since hypericin is known to form triplets and to
generate singlet oxygen with high efficiency, this
latter result is taken to confirm triplet hypericin as
a source, but not necessarily the only source, of
protons. These studies were undertaken in phos-
pholipid vesicles suspended in an aqueous medium
in order to circumvent the insolubility of hypericin
in water, to maintain a relatively close proximity of
the proton donor and acceptor, and to provide a
simplified model of the viral membrane, within which
hypericin is thought to partition.
The steady-state absorption and fluorescence spec-
tra of hypericin in DPPC vesicles in water at pH 8.4
resemble those of hypericin in DMSO or alcohols
(Figure 2), which indicates that aggregation is not
occurring. Figure 9a presents the transient at 400
nm of the 3-hexadecanoyl-7-hydroxycoumarin indica-
tor subsequent to pulsed excitation of hypericin at
490 nm. The transient is a bleach the recovery of
which is represented by two time constants: 32 and
170 ms. This signal is interpreted as proton transfer
from hypericin to the indicator on a time scale
commensurate with that of the lifetime of triplet
hypericin. Protonation of the anionic form of the
indicator decreases its population and consequently
reduces its absorbance at 400 nm. The persistent
bleach of the indicator at long times can be attributed
to the slow re-establishment of equilibrium between
the acidic and basic forms of the indicator.
Another confirmation of the assignment of the trace
in Figure 9a to a transfer of a proton from hypericin
to the indicator is that if the long-lived component is
due to the release of a proton from hypericin, its
amplitude should be “diminished” by lowering the
pH. This result is in fact observed (Figure 9b). Also,
molecular oxygen efficiently quenches triplet hyperi-
cin to form singlet oxygen. Consequently, at suf-
ficiently high oxygen levels, the concentration of
triplet hypericin should be negligible. Figure 9c
demonstrates that when the system of hypericin and
the indicator is oxygenated, no bleaching of the
indicator is observed, as is expected if the triplet is
the proton source.
Summary
In this article, we have discussed the absolute
dependence of light for antiviral activity in hypericin
and how we are exploiting this dependence, through
techniques of synthetic organic chemistry and mo-
lecular biology, to produce antiviral agents that are
capable of specifically targeting virus-infected cells.
We have also discussed the role of light in generating
excited states that possess antiviral activity and the
mechanisms by which these excited states may exert
this activity. Consequently, the tightly knit combi-
nation of the techniques of synthetic organic chem-
istry, molecular biology and virology, and physical
chemistry can be used not only to develop specificity
in an antiviral agent but also to provide a basis for
modifying and improving this antiviral activity.
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